PD1/PD-L1 (PD(L)1) inhibitors are generally more tolerable, with notable irAEs including skin rash, thyroiditis, hepatitis, joint pain, pneumonitis, and neuropathy. This evidence concerns the gene PDCD1 and pneumonitis.